Plus Therapeutics (PSTV) Depreciation & Amortization (CF) (2016 - 2025)
Plus Therapeutics has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $145000.0 for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 58.33% to $145000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $445000.0 through Dec 2025, down 48.97% year-over-year, with the annual reading at $445000.0 for FY2025, 48.97% down from the prior year.
- Depreciation & Amortization (CF) was $145000.0 for Q4 2025 at Plus Therapeutics, up from $77000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $348000.0 in Q4 2024 and troughed at $77000.0 in Q2 2025.
- The 5-year median for Depreciation & Amortization (CF) is $155000.0 (2022), against an average of $156000.0.
- Year-over-year, Depreciation & Amortization (CF) surged 130.46% in 2024 and then tumbled 61.31% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $88000.0 in 2021, then soared by 80.68% to $159000.0 in 2022, then fell by 5.03% to $151000.0 in 2023, then surged by 130.46% to $348000.0 in 2024, then tumbled by 58.33% to $145000.0 in 2025.
- Per Business Quant, the three most recent readings for PSTV's Depreciation & Amortization (CF) are $145000.0 (Q4 2025), $77000.0 (Q3 2025), and $77000.0 (Q2 2025).